Cucurbitacin I is primarily studied for its potential anticancer properties. It has been shown to inhibit the growth of various cancer cells by inducing apoptosis and disrupting cell cycle progression. Researchers are exploring its use in combination with other chemotherapeutic agents to enhance treatment efficacy. Additionally, Cucurbitacin I exhibits anti-inflammatory effects, making it a candidate for treating inflammatory diseases. Its ability to modulate signaling pathways like JAK/STAT and MAPK is also under investigation for therapeutic applications. However, further studies are needed to fully understand its mechanisms and safety profile for clinical use.